Overview
Dihexa is classified as a neurotropic peptide peptide. Synaptogenesis, memory enhancement, cognitive repair, angiotensin IV activity.
Angiotensin IV analog developed at Washington State University. Binds hepatocyte growth factor (HGF) and potentiates its binding to the c-Met receptor, triggering downstream synaptogenesis cascades in hippocampal neurons. Reported to be 7 orders of magnitude more potent than BDNF for synaptic formation in vitro. Crosses blood-brain barrier and is orally bioavailable. Produces dose-dependent improvements in spatial memory in rodent models of cognitive impairment.
Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408
Category
Neurotropic Peptide
Half-Life
48h
Route
Oral
FDA Status
Not Approved
How Does Dihexa Work?
Angiotensin IV analog developed at Washington State University. Binds hepatocyte growth factor (HGF) and potentiates its binding to the c-Met receptor, triggering downstream synaptogenesis cascades in hippocampal neurons. Reported to be 7 orders of magnitude more potent than BDNF for synaptic formation in vitro. Crosses blood-brain barrier and is orally bioavailable. Produces dose-dependent improvements in spatial memory in rodent models of cognitive impairment.
At the molecular level, Dihexa operates through pathways characteristic of the Neurotropic Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Dihexa promotes synaptogenesis and cognitive function in rodents
McCoy et al. (Journal of Pharmacology & Experimental Therapeutics): Dihexa produces dose-dependent improvements in spatial learning in rodent water maze models and promotes dendritic spine density via HGF/c-Met synaptogenesis signaling.
Evidence: preclinical[2]Angiotensin IV analogs and HGF/c-Met signaling in memory
Wright et al.: Establishes the mechanistic basis for angiotensin IV analog activity at HGF and c-Met, demonstrating memory-enhancing and neuroprotective downstream effects.
Evidence: preclinicalSafety Profile
⚠ PRECLINICAL RESEARCH ONLY. No completed human clinical trials. No established human safety profile. Extreme potency suggests very low effective doses but also potential for off-target effects. Do not use without full understanding of preclinical literature.
| Side Effect | Incidence | Severity |
|---|---|---|
| Unknown in humans | Not established | rare |
Sourcing Dihexa for Research
If you're looking to source Dihexa for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Dihexa — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.